A PHASE 2B/3, RANDOMIZED, DOUBLE-BLIND, DOSE CONFIRMING STUDY OF THE SAFETY,

$915M01FY2009RRNIH

University Of Texas Med Br Galveston, Galveston TX

Investigators

Linked publications & trials

Paper 36513449 Paper 29256039 Paper 27918196 Paper 27412890 Paper 27160204 Paper 26032499 Paper 26011707 Paper 25468473 Paper 25308445 Paper 25132995 Paper 24439095 Paper 24045284 Paper 24008390 Paper 23588945 Paper 23406616 Paper 23299598 Paper 23283360 Paper 23242157 Paper 23202876 Paper 23123437 Paper 23055137 Paper 23044556 Paper 22985607 Paper 22968888 Paper 22968233 Paper 22486454 Paper 22464408 Paper 22440820 Paper 22136297 Paper 22108096 Paper 22022507 Paper 21949554 Paper 21880862 Paper 21865352 Paper 21626041 Paper 21624416 Paper 21572159 Paper 21528164 Paper 21507260 Paper 21440944 Paper 21429562 Paper 21305820 Paper 21280007 Paper 21273076 Paper 21263308 Paper 21173642 Paper 21128320 Paper 21050666 Paper 20981823 Paper 20874659 Paper 20851528 Paper 20813056 Paper 20735212 Paper 20724580 Paper 20711085 Paper 20578825 Paper 20576209 Paper 20547663 Paper 20535455 Paper 20484484 Paper 20410772 Paper 20409740 Paper 20391489 Paper 20338575 Paper 20308936 Paper 20184413 Paper 20112391 Paper 20070283 Paper 20051096 Paper 19965801 Paper 19950257 Paper 19948245 Paper 19919871 Paper 19918038 Paper 19888036 Paper 19859015 Paper 19828686 Paper 19793553 Paper 19790132 Paper 19699838 Paper 19616456 Paper 19592280 Paper 19588121 Paper 19566588 Paper 19541257 Paper 19536857 Paper 19522649 Paper 19501860 Paper 19476171 Paper 19476170 Paper 19476169 Paper 19476168 Paper 19476167 Paper 19476166 Paper 19476165 Paper 19476163 Paper 19454587 Paper 19419806 Paper 19390002 Paper 19370045

Abstract

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The advent of combination antiretroviral therapy (ART) has significantly decreased the morbidity and mortality associated with HIV disease. However, many patients who achieve undetectable plasma HIV-1 RNA levels following treatment ultimately experience virologic failure requiring a change in their ART. Newer agents, particularly those with activity against viral isolates with resistance to currently available drugs, are clearly needed in order to extend the armory of products available to treat patients with HIV-1 infection. The nucleoside reverse transcriptase inhibitors (NRTIs) are important components of the current strategies to control HIV-1 infection. A new, well tolerated cytidine analog with an improved resistance, efficacy and safety profile would make a substantial addition to the therapeutic options for treatment experienced patients with HIV-1 infection. The objective of the study is to compare the antiretroviral efficacy of ATC to lamivudine (3TC) in treatment experienced, HIV-1 infected patients with the M184V/I mutation in reverse transcriptase.? To compare the safety and tolerability of ATC to lamivudine (3TC) in treatment experienced, HIV-1 infected patients. Patients will be randomized to one of 3 Arms to receive for up to 48 weeks in a 1:1:1 ratio: A: apricitabine 800mg BID (plus lamivudine placebo), orally B: apricitabine 1200mg BID (plus lamivudine placebo), orally C: lamivudine 150mg BID (plus apricitabine placebo), orally This study will help determine if this treatment option is effective.

View original record on NIH RePORTER →